Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05357404 · ClinicalTrials.gov registry record
Age and Sex-Specific PREValence of AcqUirEd VALVular Heart DiseasE
A clinical trial of Valvular Heart Disease, sponsored by Cardiovascular Research Foundation, New York.
- Active
- Registry status
- 2,870
- Enrollment target
- 1
- Study location
NCT05357404: Active study of Valvular Heart Disease, sponsored by Cardiovascular Research Foundation, New York.
NCT05357404 is a study of Valvular Heart Disease that is active but no longer recruiting, run by Cardiovascular Research Foundation, New York. The registered enrollment target is 2,870 participants, above the 823-participant average among 8 other Valvular Heart Disease trials with a reported enrollment target (249% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05357404, a study of Valvular Heart Disease, is active but no longer recruiting, sponsored by Cardiovascular Research Foundation, New York.
- ACTIVE NOT RECRUITING
- Registry status
- 2,870 participants
- Enrollment target
- 1
- Study location
Study Summary
The PREVUE-VALVE study will establish reliable, population-based estimates of Valvular Heart Disease (VHD) prevalence among older Americans and allow for the development and validation of several innovative tools to aid in the detection and diagnosis of Valvular Heart Disease (VHD).
Primary Outcome
The primary endpoint of the study is the presence of any significant (i.e. moderate or greater) valvular heart disease at the baseline assessment including aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, or tricuspid regurgitation.
Conditions Studied
Study Locations (1)
California
- Hawthorne Effect - Walnut Creek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,870 participants |
| Start Date | 2022-04-21 |
| Est. Completion | 2025-04 |
What the registry record for NCT05357404 still lists
NCT05357404 is an observational study that tracks outcomes without assigning an intervention. Its 2,870 participants enrollment target places it among the larger protocols in the corpus, above the 823-participant average among 8 other Valvular Heart Disease trials with a reported enrollment target (249% higher).
The record links to 1 condition, with Valvular Heart Disease appearing as the primary indexed condition, and to 0 interventions.
NCT05357404 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05357404 about?
NCT05357404 is a clinical study titled "Age and Sex-Specific PREValence of AcqUirEd VALVular Heart DiseasE". The PREVUE-VALVE study will establish reliable, population-based estimates of Valvular Heart Disease (VHD) prevalence among older Americans and allow for the development and validation of several innovative tools to aid in the detection and diagnosis of Valvular Heart Disease (VHD).
What is the current status of trial NCT05357404?
This trial is currently active not recruiting. The enrollment target is 2,870 participants. The study started on 2022-04-21. Estimated completion is 2025-04.
What conditions does trial NCT05357404 study?
This clinical trial studies the following conditions: Valvular Heart Disease.
Who is sponsoring clinical trial NCT05357404?
This trial is sponsored by Cardiovascular Research Foundation, New York, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05357404 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Valvular Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05357404's enrollment target sits among peer trials
2,870 1st of 8 higher than 8 of 8 other Valvular Heart Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Valvular Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
RECRUITING
-
Home-Based Cardiac Rehabilitation Using a Novel Mobile Health Exercise Regimen Following Transcatheter Heart Valve Interventions
RECRUITING · NA
-
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
RECRUITING
-
In Search of Best Practices for Patients With Heart Failure and Secondary Mitral Regurgitation: An Evaluation of the Inova Heart Failure Treatment Algorithm
RECRUITING
-
Abbott Structural Heart Device Registry
RECRUITING
-
PPG to Predict Ejection Fraction and Other Echographic Data in the General Population
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05624450 · 2,870 participants · Phase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
- NCT06351085 · 2,869 participants · NA
Enhancing Lung Cancer Screening Through Human-Centered Intervention
- NCT06273436 · 2,894 participants · NA
Healing, Equity, Advocacy and Respect for Mamas
- NCT06150781 · 2,842 participants
Aimovig Pregnancy Exposure Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI